We understand the challenges biotech companies face in the quest to push their biological drug candidates to market. We are hosting our 2018 Advance Biotech Grant Program, the 5th edition, open for European* biotech companies, to help you accelerate to clinic faster.
Apply now for a chance to win free process solution products and services; and/or process development support.
[*Netherlands, Belgium, Switzerland, United Kingdom, Ireland, France, Germany, Denmark, Finland, Norway, Austria, Spain, Sweden]
[** in products and services ]
To learn more on how we can help you accelerate your biotech drug development, watch this testimonial from Kilian Guse, PhD. CEO, Co-Founder GeneQuine Biotherapeutics, and recipient of the 2016 Advance Biotech Grant Program.
Questions? Contact us.
Similar programs will launch in the US and Asia in the coming months. If you are interested leave your details and we will contact you.
Unlock your molecule's potentialApply to our 2018 Advance Biotech Grant Program Today!
Bringing your molecule to market. As part of our commitment to meet the needs of the life science community, we’ve developed several programs that recognize stand-out emerging biotech companies. These programs are designed to support biotech start-ups and medium sized companies in solving their current bioprocess development challenges to bring the next generation of molecules to market.
Learn more about the ABCs of venture capital including how it works and the role of a corporate venture capital.
Learn more about the advantages to work with one source on your mAb, linker/ payload supplies and conjugation services.
Review the current dynamics in the RNA therapeutics/vaccines market with a focus on process development and manufacturing strategies.
Learn more on points to consider for successful tech transfers with a focus on cGMP training requirements.
Establishing an open dialog within the biotech community....
A report from the The Economist Intelligence Unit sponsored by Merck.
This paper, which incorporates the results of a survey of 254 pharmaceutical executives from around the world and a range of interviews with industry experts, explores in detail global pharmaceutical companies' growth strategies and their plans for managing the associated risks.